PMID- 24039692 OWN - NLM STAT- MEDLINE DCOM- 20140610 LR - 20211021 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 8 IP - 9 DP - 2013 TI - Cdk5 inhibitory peptide (CIP) inhibits Cdk5/p25 activity induced by high glucose in pancreatic beta cells and recovers insulin secretion from p25 damage. PG - e63332 LID - 10.1371/journal.pone.0063332 [doi] LID - e63332 AB - Cdk5/p25 hyperactivity has been demonstrated to lead to neuron apoptosis and degenerations. Chronic exposure to high glucose (HG) results in hyperactivity of Cdk5 and reduced insulin secretion. Here, we set out to determine whether abnormal upregulation of Cdk5/p25 activity may be induced in a pancreatic beta cell line, Min6 cells. We first confirmed that p25 were induced in overexpressed p35 cells treated with HG and increased time course dependence. Next, we showed that no p25 was detected under short time HG stimulation (4-12 hrs), however was detectable in the long exposure in HG cells (24 hrs and 48 hrs). Cdk5 activity in the above cells was much higher than low glucose treated cells and resulted in more than 50% inhibition of insulin secretion. We confirmed these results by overexpression of p25 in Min6 cells. As in cortical neurons, CIP, a small peptide, inhibited Cdk5/p25 activity and restored insulin secretion. The same results were detected in co-infection of dominant negative Cdk5 (DNCdk5) with p25. CIP also reduced beta cells apoptosis induced by Cdk5/p25. These studies indicate that Cdk5/p25 hyperactivation deregulates insulin secretion and induces cell death in pancreatic beta cells and suggests that CIP may serve as a therapeutic agent for type 2 diabetes. FAU - Zheng, Ya-Li AU - Zheng YL AD - Department of Nephrology, Ningxia People's Hospital, Yinchuan, Ningxia Province, China. FAU - Li, Congyu AU - Li C FAU - Hu, Ya-Fang AU - Hu YF FAU - Cao, Li AU - Cao L FAU - Wang, Hui AU - Wang H FAU - Li, Bo AU - Li B FAU - Lu, Xiao-Hua AU - Lu XH FAU - Bao, Li AU - Bao L FAU - Luo, Hong-Yan AU - Luo HY FAU - Shukla, Varsha AU - Shukla V FAU - Amin, Niranjana D AU - Amin ND FAU - Pant, Harish C AU - Pant HC LA - eng GR - Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural PT - Research Support, Non-U.S. Gov't DEP - 20130905 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Cdk5 inhibitory peptide, human) RN - 0 (Hypoglycemic Agents) RN - 0 (Insulin) RN - 0 (Nerve Tissue Proteins) RN - 0 (Peptide Fragments) RN - EC 2.7.11.1 (Cyclin-Dependent Kinase 5) RN - EC 2.7.11.22 (Cdk5 protein, mouse) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Animals MH - Apoptosis MH - Cyclin-Dependent Kinase 5/*metabolism MH - Diabetes Mellitus, Type 2/drug therapy/enzymology MH - Enzyme Activation MH - Glucose/pharmacology/*physiology MH - HEK293 Cells MH - Humans MH - Hypoglycemic Agents/*pharmacology MH - Insulin/*metabolism MH - Insulin Secretion MH - Insulin-Secreting Cells/*drug effects/enzymology/metabolism MH - Mice MH - Nerve Tissue Proteins/*pharmacology MH - Peptide Fragments/*pharmacology MH - Transcriptional Activation PMC - PMC3764143 COIS- Competing Interests: The authors have declared the following interests: Congyu Li is employed by Pharmerit North America. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. EDAT- 2013/09/17 06:00 MHDA- 2014/06/11 06:00 PMCR- 2013/09/05 CRDT- 2013/09/17 06:00 PHST- 2013/01/05 00:00 [received] PHST- 2013/04/02 00:00 [accepted] PHST- 2013/09/17 06:00 [entrez] PHST- 2013/09/17 06:00 [pubmed] PHST- 2014/06/11 06:00 [medline] PHST- 2013/09/05 00:00 [pmc-release] AID - PONE-D-13-01069 [pii] AID - 10.1371/journal.pone.0063332 [doi] PST - epublish SO - PLoS One. 2013 Sep 5;8(9):e63332. doi: 10.1371/journal.pone.0063332. eCollection 2013.